Close menu




December 7th, 2020 | 09:15 CET

BYD, dynaCERT, Lufthansa - Shares to take off!

  • Investments
Photo credits: pixabay.com

If you look around at the moment, it is difficult to imagine that lockdown, travel ban or border closings could soon be over. However, as stock market wisdom has taught us, the stock market, as is well known, runs ahead of the economy. That's why airlines, tour operators and other cyclical stocks are rising. The oil price has also more than doubled since its April low. There is still time to secure the fallen angels.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA26780A1084 , DE0008232125 , CNE100000296

Table of contents:


    dynaCERT - Normality comes back

    It will undoubtedly take some time until the Corona ghost has vanished, and people will focus on topics like climate change again. However, the problem remains that combustion engines emit too much pollutant and alternatives are needed urgently. Here is precisely where the Canadian Company dynaCERT Inc. comes in. The goal of the Company is to reduce the emission of pollutants from diesel-powered vehicles. To this end, retrofittable units for diesel engines have been developed that use hydrogen as a catalyst. Both CO2 emissions and fuel consumption are reduced by up to 20% at peak times.

    Total monitoring

    dynaCERT's customers are primarily fleet operators. Their trucks, which usually travel 24 hours on the North American highways, are to be equipped with the newly developed kits. With the specially programmed software "HydraLitica" it is possible to monitor the fuel savings. Building on this platform, the Company recently announced additional features such as fleet management, route planning, driver safety and load management. The Company's technology is currently being used in trial runs in more than 400 vehicles.

    The way is clear

    The technology that dynaCERT develops is right on target. It is, therefore, all the more surprising that after a high of EUR 0.60, the share price fell back to the current EUR 0.35. The reason is that the management had issued warrants with a fixed subscription price during the capital rounds last years. These warrats with a exercise price of CAD 0.35 came on the market in the previous weeks and pushed the price of the dynaCERT share to below CAD 0.50. The deadline for exercising the warrants was 01.12.2020. Thus, the way should be free for the continued positive development of the Company.

    Lufthansa - Off to the South

    Despite the still valid Corona regulations, the demand for flights over Christmas and New Year's Eve is increasing. According to company reports, bookings for Tenerife and Fuerteventura have tripled. Mexico and South Africa are also experiencing disproportionately high demand, with bookings for these destinations more than quadrupling. Nevertheless, it remains uncertain not only for the German figurehead Lufthansa but for the entire aviation industry. The question of when air traffic will return to its normal path is currently in the stars. And whether flying for business customers will ever again come close to the pre-corona level is more than questionable after the successes of Zoom & Co.

    The crane becomes slimmer

    The state has already paid EUR 8.0 billion to this German showcase airline. Of this amount, EUR 3.0 billion has already flown due to the Corona failures. The figures for the third quarter also show Lufthansa's high burn rate. A loss of EUR 5.6 billion was reported here. To stop the burning of money, in addition to the sale of the European business of the catering subsidiary LSG, a total of 29,000 jobs are to be cut by year-end. Of these, approximately 20,000 jobs are to be shed abroad, and 10,000 employees in Germany will have to vacate their chairs in 2021.

    Attractive in the long term

    After it was announced that a vaccine would soon be available to the general public, the Lufthansa share price began a flight from just under EUR 7.00 to EUR 11.00. After that, however, the share price consolidated again to below EUR 10.00. The share price is likely to remain volatile over the next few weeks and will depend on developments concerning the corona pandemic. In the long term, however, the crane should regain its wings.

    Consolidation as an opportunity

    After a new all-time high at EUR 22.40, Chinese carmaker BYD went on a consolidation course last week and only stopped at EUR 18 after a 20% slide in the support line. However, fundamental data is still correct. For example, the Company, in which entrepreneurial legend Warren Buffett also holds a stake, sold almost 54,000 vehicles in November, an increase of 30.6% over the previous year. The electric and hybrid models accounted for 26,690 of these sales, an increase of a whopping 138% compared to November 2019. Chart-wise, a further slide into the EUR 14 range is possible. In the long term, BYD will establish itself as one of the largest electric carmakers in the world.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.

    Read

    Commented by Carsten Mainitz on May 10th, 2022 | 10:39 CEST

    Zalando, Aspermont, SAP - Corona and back, the stock rebound is coming!

    • Digitization
    • Investments
    • Technology

    What would society and the economy look like without digitization? The Internet, software and smartphones have become a matter of everyday life and form the basis for communication and interaction. Corona has been an accelerator in many ways. On the other hand, pandemics and war clearly show us the limits of supposedly predictable growth with scarcity prices and supply chain disruptions. At a reduced price level, it is worth looking at "digitization stocks" that offer good opportunities.

    Read

    Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

    Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

    • Biotechnology
    • Pharma
    • Investments

    Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

    Read